Purpose Monitoring disease activity in patients with large vessel vasculitis (LVV) can be
challenging.[18F] FDG-PET/CT is increasingly used to evaluate treatment response in LVV …

The pharmacotherapy of Takayasu arteritis (TAK) with disease-modifying anti-rheumatic
drugs (DMARDs) is an evolving area. A systematic review of Scopus, Web of Science …

Objective. Disease activity in large-vessel vasculitis (LVV) is traditionally assessed by
clinical and serological variables rather than vascular imaging. This study determined the …

The use of fluorodeoxyglucose–positron emission tomography (FDG-PET) imaging to detect
vascular inflammation is increasingly common in the clinical management of patients with …

Takayasu arteritis (TA or TAK) is a chronic large vessel vasculitis with predilection to affect
the aorta and its branches. The new 2022 ACR/EULAR classification criteria for Takayasu …

Objectives: Infliximab (IFX) is widely used in patients with refractory Takayasu arteritis (TAK).
Recently, the IFX-biosimilar CT-P13 has been introduced for the treatment of inflammatory …

The primary vasculitides constitute a heterogeneous group of immune mediated diseases of
incompletely understood pathogenesis currently classified by the size of blood vessels …

Abstract 18F-fluorodeoxyglucose (FDG) positron emission tomography (PET) can detect
vascular inflammation in large-vessel vasculitis (LVV). Clinical factors that influence …

Large-vessel vasculitides (LVVs) include giant cell arteritis (GCA) and Takayasu's arteritis
(TAK). Even if similar, these two entities differ in terms of treatment and outcomes. High …

Objectives To evaluate effectiveness and safety of infliximab dose escalation in Takayasu
arteritis (TAK) patients. To identify factors associated with refractoriness to standard-dose …